SNY - IGM Biosciences Increases Focus On Autoimmune Diseases Stops All Blood Cancer-Related Studies | Benzinga
IGM Biosciences Inc (NASDAQ: IGMS) said it will focus on two strategic areas: treating colorectal cancer using IgM death receptor 5 (DR5) agonist antibodies and treating autoimmune diseases using IgM T cell engager antibodies.
As an expansion of its autoimmune efforts, the company also announced that it plans to file an Investigational New Drug (IND) ...